Catalyst
Slingshot members are tracking this event:
Bristol Myers Squibb (BMY) Reports Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Survival Results in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 19, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Opdivo, Nivolumab, Cabometyx, Cabozantib, Renal Cell Carcinoma, Cabozantinib, Checkmate
